- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07760688
Structured Periprocedural Nursing Interventions in Men Undergoing Transrectal Prostate Biopsy
Impact of Structured Periprocedural Nursing Interventions on Resilience and Anxiety in Men Undergoing Transrectal Prostate Biopsy: A Prospective Longitudinal Interventions Study With Histopathological Stratification
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a prospective, single-center, longitudinal interventional study conducted at the Department of Urology, University Clinical Hospital Mostar, Bosnia and Herzegovina.
The objective is to determine whether structured peri-procedural nursing interventions improve resilience and reduce anxiety in men undergoing transrectal prostate biopsy.
Participants will be assessed at three time points:
- baseline before the biopsy,
- 0-24 Houra after the procedure
- 2-3 weeks after the biopsy after receiving histopathological results. The study outcomes include resilience, anxiety, pain, lower urinary tract symptoms, and patients perception of nursing support.
Histopathological disgnosis (benign or malignant) will be used for subgroup analyses.
Approximately 120-140 participants are expected to be enrolled, with an anticipated final sample of approximately 100-110 participants after follow-up.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Maja Ardjelan, MSc
- Telefonnummer: 00387 36 336 162
- E-post: majaardjelan555@gmail.com
Studiesteder
-
-
Federation of Bosnia and Herzegovina
-
Mostar, Federation of Bosnia and Herzegovina, Bosnia og Herzegovina, 88000
- Rekruttering
- University Clinical Hospital Mostar
-
Ta kontakt med:
- Maja Ardjelan, MSc
- Telefonnummer: 00387 36 336 162
- E-post: majaardjelan555@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Male participants aged 40 years or older.
- Scheduled for transrectal ultrasound-guided prostate biopsy because of suspected prostate cancer.
- Able to understand the study procedures and provide written informed consent.
- Willing to complete all study assessments during the follow-up period.
Exclusion Criteria:
- Inabillity to provide informed consent.
- Severe cognitive impairment or psychiatric disorder preventing questionnaire completion.
- Previous disgnosis of prostate cancer.
- Inabillity to complete follow-up assessments.
- Withdrawal of informed consent at any time.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Structured peri-procedural nursing Intervention
All participants receive the same structured peri-procedural nursing Intervention before and after transrectal prostate biopsy.
|
The structured peri-procedural nursing Intervention includes standardized patient education, procedral preparation, comminication, emotional support, and nursing care provided before, during, and after transrectal prostate biopsy.
All participants receive the same Intervention according to the predefined study protocol.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in resilience measured by the Connor-Davidson Resilience Scale (CD-RISC-25)
Tidsramme: Baseline (7 days before biopsy), 0-24 hours after biopsy, and 2-3 weeks after biopsy.
|
To assess in resilience in men undergoing transrectal prostate biopsy after structured peri-procedural nursing Intervention.
|
Baseline (7 days before biopsy), 0-24 hours after biopsy, and 2-3 weeks after biopsy.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in anxiety measured by the Hamilton Anxiety Rating Scale (HAM-A)
Tidsramme: Baseline (7 days before biopsy), and 2-3 weeks after biopsy following disclosure of histopathological results.
|
To assess changes in anxiety levels in men undergoing transrectal prostate biopsy following structured peri-procedural nursing Intervention.
|
Baseline (7 days before biopsy), and 2-3 weeks after biopsy following disclosure of histopathological results.
|
|
Change in lower urinary tract symptoms associated with the biopsy procedure and recovery.
Tidsramme: Baseline (7 days before biopsy), 0-24 hours after biopsy, and 2-3 weeks after biopsy.
|
To assess changes in lower urinary tract symptoms associated with the biopsy procedure and recovery.
|
Baseline (7 days before biopsy), 0-24 hours after biopsy, and 2-3 weeks after biopsy.
|
|
Pain intensity measured by the Numeric Rating Scale (NRS)
Tidsramme: 0-24 hours after biopsy.
|
To assess pain intensity experienced after transrectal prostate biopsy.
|
0-24 hours after biopsy.
|
|
Perception of nursing care measured by a structured patient questionnaire
Tidsramme: 0-24 hours after biopsy and 2-3 weeks after biopsy.
|
To assess patients perception of peri-procedural nursing care, comminication, emotional support, and information provided.
|
0-24 hours after biopsy and 2-3 weeks after biopsy.
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Histopathological disgnosis after prostate biopsy
Tidsramme: 2-3 weeks after prostate biopsy, when histopathological results are disclosed.
|
Histopathological biopsy results will be recorded and participants will be stratified into benign and malignant disgnosis groups for pre-specified subgroup analyses.
|
2-3 weeks after prostate biopsy, when histopathological results are disclosed.
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Maja Ardjelan, MSc, University of Mostar
- Studiestol: Katica Pavlović, MD, PhD, University of Mostar
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Psykiske lidelser
- Genitale neoplasmer, hanner
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kjønnssykdommer, mannlige
- Prostata sykdommer
- Mannlige urogenitale sykdommer
- Urologiske manifestasjoner
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Prostatiske neoplasmer
- Angstlidelser
- Nedre urinveissymptomer
Andre studie-ID-numre
- No. 229/26
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .